Inflammatory diseases including
COVID-19 are associated with a
cytokine storm characterized by high
interleukin-6 (IL-6) titers. In particular, while recent studies examined
COVID-19 associated arrhythmic risks from cardiac injury and/or from
pharmacotherapy such as the combination of
azithromycin (AZM) and
hydroxychloroquine (HCQ), the role of
IL-6 per se in increasing the arrhythmic risk remains poorly understood. The objective is to elucidate the electrophysiological basis of
inflammation-associated arrhythmic risk in the presence of AZM and HCQ.
IL-6, AZM and HCQ were concomitantly administered to guinea pigs in-vivo and in-vitro. Electrocardiograms, action potentials and ion-currents were analyzed.
IL-6 alone or the combination AZM + HCQ induced mild to moderate reduction in heart rate, PR-interval and corrected QT (QTc) in-vivo and in-vitro. Notably,
IL-6 alone was more potent than the combination of the two drugs in reducing heart rate, increasing PR-interval and QTc. In addition, the in-vivo or in-vitro combination of IL-6 + AZM + HCQ caused severe
bradycardia, conduction abnormalities, QTc prolongation and
asystole. These electrocardiographic abnormalities were attenuated in-vivo by
tocilizumab (TCZ), a
monoclonal antibody against
IL-6 receptor, and are due in part to the prolongation of action potential duration and selective inhibition of Na+, Ca2+ and K+ currents.
Inflammation confers greater risk for
arrhythmia than the
drug combination therapy. As such, in the setting of elevated
IL-6 during
inflammation caution must be taken when co-administering drugs known to predispose to fatal arrhythmias and TCZ could be an important player as a novel
anti-arrhythmic agent. Thus, identifying
inflammation as a critical culprit is essential for proper management.